16130dkk
4,2 %
Date:2024-12-20Time:16:59:33Latest report:Q3-2024List:Large CapTicker:ALK B
Market Cap:35 340 mdkkEnterprise Value:35 545 mdkkNet Sales:5 383 mdkkEarnings:785,0 mdkkEmployees:0ISIN:DK0061802139

Ratios

10-year key figure history for ALK-Abello turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for ALK-Abello with index and moving average MA50 and MA200.

Stockprice:161,30
MA50:161,32
MA200:153,83
Price/MA200:3,1 %
RSI (14):50,4
Price/MA50:-1,7 %

Description

Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Pharmaceuticals